Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...
This study is led by Dr. Nan Qiao (Laboratory of Health Intelligence, Huawei Cloud Computing Technologies), Dr. Hualiang Jiang (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) and ...
Implementing the Medicare $2 drug list model would have reduced out-of-pocket spending by 63% for Part D beneficiaries in 2021. The model caps cost-sharing at $2 for a 30-day supply of 101 generic ...
The proposed Medicare High-Value Drug List Model, also known as the Medicare $2 Drug List, could have modestly reduced out-of-pocket costs for 38% of beneficiaries if implemented in 2021. To do so, ...
President Donald Trump says it's the biggest thing to happen to drug pricing. The White House says 9 drug manufacturers have agreed to give Medicaid in all 50 states access to most favored nation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback